Zydus Cadila seeks permission to use ZyCov-D vaccine, know what is special, Zydus Cadila seeks permission to use ZyCov-D vaccine, know what is special
Eye on ZyCov-D vaccine, what is special
- ZyCov-D is the first palsmid vaccine to be administered without a needle
- Testing has been done on 28 thousand people, test done in second wave
- If permission is given by DCGI, then this will be the second indigenous vaccine.
At present, CovaShield as well as Covaccine is being used for vaccination in the country. Apart from these two vaccines, Russia’s Sputnik V has also been approved. Amidst all this, Zydus Cadila has requested emergency use approval for its ZyCoV-D three-dose COVID shot which is the “world’s first plasmid DNA vaccine” with the Drug Controller General of India (DCGI).
zydus cadilla vaccine needle free
The shot is “needle-free,” according to the company, which is safe for children. The company plans to manufacture 10-12 million doses of the shot annually. India’s Drug Controller General’s approval for ZyCoV-D will make it the fifth vaccine for use in India after Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin, Russia’s Sputnik V and US-made Moderna.
Test on 28 thousand people, second phase sample also test
Zydus says it has conducted the largest clinical trial for its COVID-19 vaccine so far in over 50 centers in India. This was also the first time that any COVID-19 vaccine has been tested in the adolescent population in the 12-18 year age group in India. About a thousand subjects were enrolled in this age group and the vaccine was found to be safe and very effective. was found to be tolerable. The tolerability profile was similar to that observed in the adult population.
67% Primarily Effective
A primary efficacy of 66.6% has been obtained for symptomatic RT-PCR positive cases in the interim analysis. Whereas, no common cases of COVID-19 disease were observed in the third dose vaccine arm post administration, suggesting 100% efficacy for moderate disease. There was no serious case or death due to this.
ZyCoV-D had already demonstrated strong immunogenicity and tolerability and safety profile in previously conducted favorable phase I/II clinical trials. With phases one and two and phase III clinical trials supervised by an independent Data Safety Monitoring Board (DSMB). ZyCoV-D is a plasmid DNA vaccine that, when injected, produces the spike protein of the SARS-CoV-2 virus. Produces and elicits an immune response mediated by the cellular and humoral arms of the human immune system, which play an important role in protection against disease. It also prevents the spread of the virus.
#Zydus #Cadila #seeks #permission #ZyCovD #vaccine #special #Zydus #Cadila #seeks #permission #ZyCovD #vaccine #special